Tibbitts J[au] - Search Results

Year	Number of Results
1989	1
1999	1
2000	1
2003	1
2004	1
2007	1
2010	6
2011	4
2012	10
2013	3
2014	4
2015	5
2016	2
2017	2
2018	2
2019	1
2022	1
2023	0

1

Pharmacokinetic considerations for antibody drug conjugates.

Lin K, Tibbitts J. Lin K, et al. Among authors: tibbitts j. Pharm Res. 2012 Sep;29(9):2354-66. doi: 10.1007/s11095-012-0800-y. Epub 2012 Jun 28. Pharm Res. 2012. PMID: 22740180 Review.

2

Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer.

Burris HA 3rd, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD. Burris HA 3rd, et al. Among authors: tibbitts j. Clin Breast Cancer. 2011 Oct;11(5):275-82. doi: 10.1016/j.clbc.2011.03.018. Epub 2011 May 18. Clin Breast Cancer. 2011. PMID: 21729661 Review.

3

Issues related to the use of canines in toxicologic pathology--issues with pharmacokinetics and metabolism.

Tibbitts J. Tibbitts J. Toxicol Pathol. 2003 Jan-Feb;31 Suppl:17-24. doi: 10.1080/01926230390174896. Toxicol Pathol. 2003. PMID: 12597427 Review.

4

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.

Ménochet K, Yu H, Wang B, Tibbitts J, Hsu CP, Kamath AV, Richter WF, Baumann A. Ménochet K, et al. Among authors: tibbitts j. MAbs. 2022 Jan-Dec;14(1):2145997. doi: 10.1080/19420862.2022.2145997. MAbs. 2022. PMID: 36418217 Review.

5

Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.

Brennan FR, Cauvin A, Tibbitts J, Wolfreys A. Brennan FR, et al. Among authors: tibbitts j. Drug Dev Res. 2014 May;75(3):115-61. doi: 10.1002/ddr.21173. Epub 2014 Apr 29. Drug Dev Res. 2014. PMID: 24782266 Review.

6

Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.

Tibbitts J, Canter D, Graff R, Smith A, Khawli LA. Tibbitts J, et al. MAbs. 2016;8(2):229-45. doi: 10.1080/19420862.2015.1115937. Epub 2015 Dec 4. MAbs. 2016. PMID: 26636901 Free PMC article. Review.

7

Pharmacokinetics and ADME characterizations of antibody-drug conjugates.

Lin K, Tibbitts J, Shen BQ. Lin K, et al. Among authors: tibbitts j. Methods Mol Biol. 2013;1045:117-31. doi: 10.1007/978-1-62703-541-5_7. Methods Mol Biol. 2013. PMID: 23913144

8

Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.

Shirai CL, Ley JN, White BS, Kim S, Tibbitts J, Shao J, Ndonwi M, Wadugu B, Duncavage EJ, Okeyo-Owuor T, Liu T, Griffith M, McGrath S, Magrini V, Fulton RS, Fronick C, O'Laughlin M, Graubert TA, Walter MJ. Shirai CL, et al. Among authors: tibbitts j. Cancer Cell. 2015 May 11;27(5):631-43. doi: 10.1016/j.ccell.2015.04.008. Cancer Cell. 2015. PMID: 25965570 Free PMC article.

9

Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.

Blaich G, Baumann A, Kronenberg S, de Haan L, Ulrich P, Richter WF, Tibbitts J, Chivers S, Tarcsa E, Caldwell R, Crameri F. Blaich G, et al. Among authors: tibbitts j. Regul Toxicol Pharmacol. 2016 Oct;80S:S1-S14. doi: 10.1016/j.yrtph.2016.08.012. Epub 2016 Aug 27. Regul Toxicol Pharmacol. 2016. PMID: 27578450

10

Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.

Ulrich P, Blaich G, Baumann A, Fagg R, Hey A, Kiessling A, Kronenberg S, Lindecrona RH, Mohl S, Richter WF, Tibbitts J, Crameri F, Weir L. Ulrich P, et al. Among authors: tibbitts j. Regul Toxicol Pharmacol. 2018 Apr;94:91-100. doi: 10.1016/j.yrtph.2018.01.013. Epub 2018 Jan 28. Regul Toxicol Pharmacol. 2018. PMID: 29355662

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results